The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | LOXO-305 as a novel treatment in previously treated NHL: results from the BRUIN trial
Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of BRUIN (NCT03740529), a multicenter Phase I/II trial aiming to evaluate the efficacy and safety of LOXO-305, a highly selective BTK inhibitor, in patients with B-cell malignancies who have received more than 2 prior therapies. No dose-limiting toxicities were reported and treatment-related adverse events were scarce. The BRUIN trial shows that LOXO-305 has promising efficacy in previously treated MCL, WM as well as other non-Hodgkin lymphomas (NHL). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Michael Wang has received grants from Pharmacyclics, Celgene, Janssen, AstraZeneca/Acerta, Juno, Loxo Oncology, VelosBio, BioInvent, Kite Pharma, Verastem, BeiGene, Eli Lilly, InnoCare and Molecular Templates; has received personal fees from Pharmacyclics, Celgene, Janssen, AstraZeneca/Acerta, OMI, Pulse Biosciences, Juno, Loxo Oncology, VelosBio, Targeted Oncology, Kite Pharma, Guidepoint Global, BeiGene, InnoCare and Oncternal; has received non-financial support from Pharmacyclics, Celgene, Janssen and OMI.
